Yes — with GLP-1 medications such as semaglutide or tirzepatide, a meaningful part of the weight lost can be muscle, not just fat, and it is not because the drug directly breaks down muscle. It happens because a fast drop in food intake and lower activity, without enough protein and strength training, often leave the body with little reason to spare muscle over fat. InBody does not evaluate the medication or its safety here — it shows whether the weight coming off is mostly fat, or whether muscle is going with it.
GLP-1 medications are named after glucagon-like peptide-1, a hormone the body releases after eating that affects appetite, stomach emptying and blood sugar. The group includes active substances such as semaglutide and liraglutide, while the newer tirzepatide combines a GLP-1 and GIP effect. These medications were first used for type 2 diabetes and are now increasingly prescribed specifically for weight management.
The effect on body weight tends to be faster and larger than what most people experience with diet alone. Lower appetite and slower stomach emptying make it easier to eat less without the constant hunger many diets involve. That speed is part of why GLP-1 therapy has become so popular — and it is also exactly why the question of what is actually being lost along the way matters.
The body does not automatically pull energy only from fat during a deficit — it draws from whatever is available, and muscle is always part of that equation. Clinical research on GLP-1 therapy, including the large trial programs behind semaglutide and tirzepatide (often referenced as the STEP and SURMOUNT trial series), has repeatedly described that a meaningful share of total weight lost can be fat-free mass, which includes muscle, not fat alone. The exact proportion varies between studies and individuals, but the pattern is consistent: the faster and deeper the weight loss, the higher the risk that muscle is part of it.
Appetite suppression often lowers total protein intake along with everything else, and daily activity can drop too, simply because there is less energy or motivation to move during rapid weight loss. Without a deliberate strength-training stimulus and enough protein, the body has little reason to protect muscle ahead of fat.
This mechanism overlaps with sarcopenia, the loss of muscle mass and strength usually discussed in the context of ageing. During fast, medically supported weight loss, the same underlying pattern — losing active tissue without enough compensation — can show up in younger adults too, if the weight loss is not paired with the right diet and training. It is not the same diagnosis, but the principle of protecting muscle during weight loss is the same one.
A bathroom scale gives one number that cannot tell you whether the kilograms lost were fat or muscle. InBody uses bioelectrical impedance to estimate fat mass and muscle mass separately, so you can see which direction each one is actually moving.
During GLP-1 therapy, that turns one line on a scale into two curves — fat and muscle. The pattern worth aiming for is fat mass dropping clearly while muscle mass stays roughly stable or drops only slightly. If muscle is falling faster than the fat trend would suggest, that is a signal to adjust diet or training, or bring it up with the prescribing doctor.
Two people who lose the same five kilograms over the same period can end up in very different places, depending on what that weight loss is actually made of. The comparison below illustrates two simplified patterns for the same amount of scale weight lost.
| Area | Metric | Fat-dominant weight loss | Weight loss with notable muscle loss |
|---|---|---|---|
| Fat mass | Drops clearly and makes up most of the loss. | Drops, but is not the only part of the loss. | |
| Muscle mass | Stays roughly stable. | Drops noticeably alongside fat. | |
| Resting energy expenditure | Drops only slightly, since muscle is preserved. | Drops more, since active tissue is reduced. | |
| Strength and everyday energy | Usually holds up or dips only a little. | Grip strength and everyday performance often drop too. | |
| Risk after stopping therapy | Lower risk of quickly regaining fat. | Higher risk that regained weight is mostly fat. |
Protein matters more during GLP-1 therapy than in typical dieting, because overall food intake tends to be lower and it becomes easier to fall short of what muscle needs to be maintained. Many expert recommendations for medically supported weight loss emphasize adequate protein spread evenly across the day, rather than one large meal.
Strength training is the second pillar — it gives the body a clear signal that muscle is still needed, even when total energy intake is lower. It does not need to be an intense program; two to three shorter strength sessions a week already make a difference compared with no resistance training at all. Some people also consider creatine alongside this combination to support strength and recovery, but the right approach and dosage is a conversation for a doctor or nutrition professional, not a decision to make alone.
Sleep and stress management are easy to overlook here, yet they affect appetite, recovery from training and how the body handles an energy deficit. Over a few days their effect is easy to ignore; over months of weight loss, it usually shows up in the final balance between fat lost and muscle kept.
For results to be comparable, measurements should happen under similar conditions — a similar time of day, similar hydration, no training right before the test. That matters for any InBody tracking, but it matters more during rapid weight loss, because more is changing in the body at once.
Measurement frequency should match the pace of change, not the urge to check constantly. During faster weight loss, checking roughly every few weeks is usually enough to catch an unwanted muscle trend early, without turning small fluctuations between visits into unnecessary worry.
The result history in the client portal is useful here, since it lines up measurements over time and shows how the fat and muscle curves move together, rather than comparing only the last two results in isolation. A longer timeline makes it much easier to tell a real trend apart from normal variation between visits.
InBody does not evaluate the safety or suitability of GLP-1 treatment, does not assess dosing, and does not replace lab work or follow-up with the prescribing doctor. It is a supporting tool for tracking body composition alongside medical care, not instead of it.
If muscle mass is clearly dropping faster than fat, or you notice significant fatigue, dizziness, loss of strength in everyday tasks or other unusual symptoms, talk to your doctor rather than waiting for the next InBody measurement. The same applies to any decision about adjusting or stopping the medication — that is always a decision for the prescribing doctor, not something to conclude from a result sheet.
About the measurement
The main page about body composition measurement, result output and the visit.
More reading
FAQ
For many people, yes — not because the medication directly breaks down muscle, but because a fast drop in food intake and lower activity, without enough protein and strength training, often means part of the weight lost is muscle along with fat. How much varies between individuals and can be influenced by diet and training.
A regular scale cannot tell you, since it only shows total weight change. You need a method that separates fat mass from muscle mass, such as InBody, and to track both over repeated measurements taken under similar conditions.
Yes — strength training combined with adequate, evenly spread protein intake are among the main steps that lower the risk of muscle loss during GLP-1 therapy. The right protein target and training approach are best discussed with a nutrition professional or trainer, ideally in line with guidance from the prescribing doctor.
No. InBody is a supporting tool for tracking body composition, not a replacement for medical monitoring, lab tests or dose adjustments. Decisions about the treatment itself always belong to the prescribing doctor.
During faster weight loss, checking roughly every few weeks is usually enough to catch an unwanted muscle-loss trend early, without letting small fluctuations between visits lead to premature conclusions.
Sources
When weight loss is supported by GLP-1 medication, tracking fat mass and muscle mass separately over time matters more than a single number on the scale. An InBody measurement at Moje InBody in Prague shows which direction each curve is actually moving, and together with tools like grip strength or Max Pulse, it fills in a fuller picture of how the body is responding to the change.